Fig. 3 | Cellular & Molecular Immunology

Fig. 3

From: Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods

Fig. 3

Frequency of neutralizing antibodies against SARS-CoV-2 measured by a pseudotyped virus neutralization test (pVNT) based on SARS-CoV-2 S protein-pseudotyped VSV. A Example of pVNT results. Sera from COVID-19 convalescent patients with mild or severe disease—but not from healthy controls (HC)—suppress entry of replication-defective VSV particles carrying the SARS-CoV-2 S protein into host cells (filled bars); neither sera suppressed the entry of control particles carrying the G-protein of VSV entry (open bars). Red lines indicate levels of 50 or 90% suppression of virus entry as indicated. Relative distributions of SARS-CoV-2 neutralizing serum titers that result in (B) 90% (pVNT90) or (C) 50% (pVNT50) reduction of luciferase production, as described in (A). ***P < 0.001; Fisher’s exact test (HC vs. mild or severe) or the Chi-squared test was used to assess the trend (mild vs. severe)

Back to article page